5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 8.38▼ | 8.42▼ | 8.40▼ | 8.38▼ | 8.36▲ |
MA10 | 8.40▼ | 8.41▼ | 8.40▼ | 8.42▼ | 8.93▼ |
MA20 | 8.41▼ | 8.41▼ | 8.44▼ | 8.39▼ | 9.01▼ |
MA50 | 8.41▼ | 8.43▼ | 8.37▲ | 9.12▼ | 8.33▲ |
MA100 | 8.41▼ | 8.38▼ | 8.33▲ | 8.99▼ | 7.18▲ |
MA200 | 8.44▼ | 8.33▲ | 8.51▼ | 8.43▼ | 9.17▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.006▼ | -0.002▼ | -0.008▼ | 0.059▲ | -0.236▼ |
RSI | 33.136▼ | 43.819▼ | 47.201▼ | 45.251▼ | 46.210▼ |
STOCH | 19.048▼ | 44.940 | 44.873 | 37.318 | 7.419▼ |
WILL %R | -85.714▼ | -92.857▼ | -57.778 | -62.602 | -86.471▼ |
CCI | -161.251▼ | -82.879 | -45.714 | 33.515 | -85.576 |
Monday, August 11, 2025 04:43 AM
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Dr. Helen Thackray, chief research and development officer, will leave ...
|
Monday, August 11, 2025 04:12 AM
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Dr. Helen Thackray, chief research and development officer, will leave the company September 1, 2025 and transition into an advisory ...
|
Tuesday, August 05, 2025 12:12 AM
BioCryst Pharmaceuticals Inc (BCRX) reports a 45% increase in ORLADEYO revenue and significant debt repayment, positioning itself for future growth in the rare disease market.
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
15/08/25 | 8.37 | 8.52 | 8.36 | 8.37 | 2,586,789 |
14/08/25 | 8.43 | 8.50 | 8.27 | 8.45 | 2,237,478 |
13/08/25 | 8.40 | 8.64 | 8.395 | 8.53 | 3,706,329 |
12/08/25 | 8.26 | 8.40 | 8.22 | 8.35 | 2,311,352 |
11/08/25 | 8.20 | 8.29 | 8.08 | 8.20 | 2,210,467 |
08/08/25 | 8.38 | 8.45 | 8.26 | 8.30 | 1,823,049 |
07/08/25 | 8.59 | 8.65 | 8.30 | 8.35 | 2,328,105 |
06/08/25 | 8.37 | 8.61 | 8.34 | 8.60 | 2,676,584 |
05/08/25 | 8.62 | 8.69 | 8.33 | 8.36 | 4,171,080 |
04/08/25 | 9.14 | 9.14 | 8.095 | 8.73 | 9,702,524 |
|
|
||||
|
|
||||
|
|